GSK PLC-SPON ADR (GSK)

US37733W2044 - ADR

42.87  -0.12 (-0.28%)

After market: 42.87 0 (0%)

News Image
21 hours ago - Investor's Business Daily

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

News Image
3 days ago - WuXi Biologics

WuXi Biologics Reports Solid 2023 Annual Results

Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Million Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong...

News Image
5 days ago - The Motley Fool

Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?

Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.

News Image
15 days ago - Market News Video

November 15th Options Now Available For GSK

News Image
15 days ago - Zacks Investment Research

GSK PLC Sponsored ADR (GSK) Is a Trending Stock: Facts to Know Before Betting on It

Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

News Image
16 days ago - InvestorPlace

Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio

One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.

News Image
18 days ago - InvestorPlace

Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead

Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success.

News Image
22 days ago - InvestorPlace

3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise

Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.

News Image
22 days ago - Market News Video

GSK April 26th Options Begin Trading

News Image
a month ago - Zacks Investment Research

Glaxo (GSK) Up 3.1% Since Last Earnings Report: Can It Continue?

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News Image
a month ago - Zacks Investment Research

Investors Heavily Search GSK PLC Sponsored ADR (GSK): Here is What You Need to Know

Zacks.com users have recently been watching Glaxo (GSK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

News Image
a month ago - Seeking Alpha

Pfizer’s RSV shot maintains protective efficacy through two seasons (NYSE:PFE)

Pfizer reports positive data for Abrysvo vaccine, showing high efficacy in preventing respiratory syncytial virus (RSV) in adults 60 years and older.

News Image
a month ago - Seeking Alpha

GSK’s gonorrhoea drug achieves efficacy goal in pivotal trial (NYSE:GSK)

GSK announces positive results from pivotal trial of oral gonorrhoea drug, gepotidacin.

News Image
a month ago - InvestorPlace

3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List

Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.

News Image
a month ago - Investor's Business Daily

Why Range-Bound Moderna Could Get A Boost On Its Fourth-Quarter Report

The company unexpectedly came in with fourth-quarter earnings that beat projections.

News Image
a month ago - InvestorPlace

3 Low-Priced Dividend Stocks With Solid Fundamentals & Growth

Solid dividend stocks with good growth outlooks can deliver high profits for investors and should become more popular as interest rates drop. 

News Image
a month ago - Seeking Alpha

AnaptysBio stock gains on bullish view from Piper Sandler

AnaptysBio (ANAB) stock rises after Piper Sandler initiated coverage with a bullish view, citing a catalyst-rich period for the biotech in 2024/25. Read more here.

News Image
a month ago - Seeking Alpha

GSK stock raised to Buy at Citi on Blenrep data (NYSE:GSK)

Citi upgrades GSK (GSK) to Buy following positive Phase 3 data for its multiple myeloma drug, Blenrep. Read more here.

News Image
2 months ago - Seeking Alpha

Moderna stock drops on data for RSV shot (NASDAQ:MRNA)

Shares of Moderna (MRNA) dropped as concerns arise over the long-term efficacy of its experimental vaccine against respiratory syncytial virus (RSV). Read more here.